Follow-up data regarding the cardiorenal outcomes or metabolic changes including diabetes on the patients treated with CD38 antibodies may be useful to clarify the role of CD38 on cardiorenal metabolic disease in humans. The gene discussed is CD38; the disease is diabetes mellitus.